Skip to content
E2 · Observational studyCohortPEM unclearCross-sectionalPeer-reviewed
Standard · 3 min

[Pilot estimation of the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome and multiple chemical sensitivity in the adult population of the Community of Madrid (Spain) using Primary Care-based sampling].

Alameda Cuesta, Almudena, Cid Expósito, Gema, Nieto Muñoz, Cristina et al.

Revista espanola de salud publica2026PubMed

Design
Cross-sectional
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

A Spanish research team surveyed adults in Madrid using standardized questionnaires to estimate how many people have ME/CFS and multiple chemical sensitivity (MCS). In this pilot phase, they found that approximately 2.26% of respondents screened positive for ME/CFS and 2.64% for MCS—rates much higher than expected for rare diseases. However, this is an early report from a partial sample (280 of 530 participants completed screening), so these figures are preliminary estimates rather than confirmed population rates.

Why It Matters

This study addresses a critical gap in ME/CFS epidemiology: reliable prevalence data are scarce in most countries, and clinical recognition remains hindered by diagnostic variability. The observed prevalence rates in Madrid (2.26%) substantially exceed the threshold for rare-disease designation, suggesting ME/CFS and MCS represent a significant public health burden deserving greater clinical and research attention. The finding that half of ME/CFS cases co-occurred with MCS may inform future investigation of overlapping mechanisms or diagnostic criteria.

Observed Findings

What the study reports it measured.

  • In the pilot sample (n=280), 2.26% of respondents met screening criteria for ME/CFS using DSQ-SF, SF-36, and QEESI questionnaires.
  • In the same sample, 2.64% met screening criteria for MCS.
  • Approximately 50% of individuals who screened positive for ME/CFS also screened positive for MCS (estimated dual-condition prevalence 1.13%).
  • Participation rate was 52.8% (280 of 530 consented adults completed screening).
  • These prevalence estimates exceed the epidemiological threshold for rare-disease classification.

Inferred Conclusions

What the authors interpret from those results.

  • The authors interpret the observed prevalence rates as indicating that ME/CFS and MCS represent significant epidemiological burdens in the Madrid population, contrary to their current classification as rare diseases.
  • The high co-occurrence of ME/CFS and MCS criteria suggests potential shared pathogenic pathways or diagnostic overlap, though the cross-sectional design does not establish mechanism.
  • The authors propose that social invisibility and diagnostic variability have historically underestimated disease burden, and that primary-care-based sampling may help identify previously unrecognised cases.

Remaining Questions

  • Will the prevalence estimates hold in the full planned sample (n=2,000) and across other Spanish regions?
  • How do the questionnaire-based case definitions (DSQ-SF, SF-36, QEESI) align with clinical diagnosis by ME/CFS specialists?
  • What clinical or biological factors are associated with the observed co-occurrence of ME/CFS and MCS criteria?
  • Can the low completion rate (52.8%) introduce selection bias, and do non-completers differ systematically from those screened?

What This Study Does Not Prove

This pilot does not establish the true population prevalence of ME/CFS in Madrid or Spain—it represents a partial sample with low completion rate. The cross-sectional design does not permit investigation of causation, natural history, or risk factors. The study does not validate the questionnaire-based case definitions used (DSQ-SF, SF-36, QEESI) against clinical diagnosis or gold-standard criteria. Results cannot be generalised beyond the sampled primary care population or region without completion of the full planned study (n=2,000).

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Alameda Cuesta, Almudena, Cid Expósito, Gema, Nieto Muñoz, Cristina, Talavera Sáez, Ana, Lizcano Alvárez, Ángel, Blanco Abril, Saray, et al. (2026). [Pilot estimation of the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome and multiple chemical sensitivity in the adult population of the Community of Madrid (Spain) using Primary Care-based sampling].. Revista espanola de salud publica. https://pubmed.ncbi.nlm.nih.gov/43046944/

BibTeX

@article{mecfsatlas-alameda-cuesta-2026-pilot-estimation,
  author  = {Alameda Cuesta, Almudena and Cid Expósito, Gema and Nieto Muñoz, Cristina and Talavera Sáez, Ana and Lizcano Alvárez, Ángel and Blanco Abril, Saray and Oter Quintana, Cristina and Esteban Hernández, Jesús},
  title   = {[Pilot estimation of the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome and multiple chemical sensitivity in the adult population of the Community of Madrid (Spain) using Primary Care-based sampling].},
  journal = {Revista espanola de salud publica},
  year    = {2026},
  note    = {PubMed: 43046944},
  url     = {https://www.mecfsatlas.com/evidence/alameda-cuesta-2026-pilot-estimation},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-19. https://www.mecfsatlas.com/evidence/alameda-cuesta-2026-pilot-estimation

Contribute

Private, reviewed by a human. Not a public comment thread.